Targeting RBM5 may help disrupt 'undruggable' MYC in childhood leukemia
Scientists from St. Jude Children's Research Hospital and collaborators have identified the RNA-binding protein RBM5 as a potential vulnerability in a set of difficult-to-treat childhood leukemias. They characterized how RBM5 regulates and interacts with the well-known cancer-dri